Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/90294
PIRA download icon_1.1View/Download Full Text
Title: EPHB2 activates β-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma
Authors: Leung, HW 
Leung, CON 
Lau, EY
Chung, KPS 
Mok, EH 
Lei, MML
Leung, RWH 
Tong, M
Keng, VW 
Ma, C 
Zhao, Q 
Ng, IOL
Ma, S
LEE, TK 
Issue Date: 15-Jun-2021
Source: Cancer research, 15 June 2021, v. 81, no. 12, p. 3229-3240.
Abstract: The survival benefit derived from sorafenib treatment for patients with hepatocellular carcinoma (HCC) is modest due to acquired resistance. Targeting cancer stem cells (CSC) is a possible way to reverse drug resistance; however, inhibitors that specifically target liver CSCs are limited. In this study, we established two sorafenib-resistant, patient-derived tumor xenografts (PDX) that mimicked development of acquired resistance to sorafenib in HCC patients. RNA-sequencing analysis of sorafenib-resistant PDXs and their corresponding mock controls identified EPHB2 as the most significantly upregulated kinase. EPHB2 expression increased stepwise from normal liver tissue to fibrotic liver tissue to HCC tissue and correlated with poor prognosis. Endogenous EPHB2 knockout showed attenuation of tumor development in mice. EPHB2 regulated the traits of liver CSCs; similarly, sorted EPHB2High HCC cells were endowed with enhanced CSC properties when compared with their EPHB2Low counterparts. Mechanistically, EPHB2 regulated cancer stemness and drug resistance by driving the SRC/AKT/GSK3β/β-catenin signaling cascade, and EPHB2 expression was regulated by TCF1 via promoter activation, forming a positive Wnt/β-catenin feedback loop. Intravenous administration of rAAV-8-shEPHB2 suppressed HCC tumor growth and significantly sensitized HCC cells to sorafenib in an NRAS/AKT-driven HCC immunocompetent mouse model. Targeting a positive feedback loop involving the EPHB2/β-catenin axis may be a possible therapeutic strategy to combat acquired drug resistance in HCC.
Publisher: American Association for Cancer Research
Journal: Cancer research 
ISSN: 0008-5472
EISSN: 1538-7445
DOI: 10.1158/0008-5472.CAN-21-0184
Rights: ©2021 American Association for Cancer Research.
This manuscript has been accepted for publication in Molecular Biotechnology, which is published by the American Association for Cancer Research. The final published version of record is available at https://dx.doi.org/10.1158/0008-5472.CAN-21-0184
Appears in Collections:Journal/Magazine Article

Files in This Item:
File Description SizeFormat 
Leung_EPHB2_Activates.pdfPreprint version10.71 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Author’s Original
Access
View full-text via PolyU eLinks SFX Query
Show full item record

Page views

26
Citations as of May 15, 2022

Downloads

84
Citations as of May 15, 2022

SCOPUSTM   
Citations

8
Citations as of May 12, 2022

WEB OF SCIENCETM
Citations

7
Citations as of May 19, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.